These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The therapeutic potential of antisense oligonucleotides. Sharma HW; Narayanan R Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067 [TBL] [Abstract][Full Text] [Related]
3. Clinical development of antisense oligonucleotides as anti-cancer therapeutics. Chen HX Methods Mol Med; 2003; 75():621-36. PubMed ID: 12407768 [No Abstract] [Full Text] [Related]
4. Recent status of the antisense oligonucleotide approaches in oncology. Ma L; Calvo F Fundam Clin Pharmacol; 1996; 10(2):97-115. PubMed ID: 8737953 [TBL] [Abstract][Full Text] [Related]
5. Antisense therapy for cancer. Gleave ME; Monia BP Nat Rev Cancer; 2005 Jun; 5(6):468-79. PubMed ID: 15905854 [TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical experience of antisense therapy for solid tumors. Webb MS; Zon G Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760 [TBL] [Abstract][Full Text] [Related]
7. Antisense approaches to cancer gene therapy. Mercola D; Cohen JS Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254 [TBL] [Abstract][Full Text] [Related]
9. Antisense strategy: biological utility and prospects in the treatment of hematological malignancies. Warzocha K; Wotowiec D Leuk Lymphoma; 1997 Jan; 24(3-4):267-81. PubMed ID: 9156656 [TBL] [Abstract][Full Text] [Related]
10. Antisense anticancer oligonucleotide therapeutics. Wang H; Prasad G; Buolamwini JK; Zhang R Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878 [TBL] [Abstract][Full Text] [Related]
11. [Prospects for antisense therapy]. Maekawa T Rinsho Ketsueki; 1995 May; 36(5):410-8. PubMed ID: 7783344 [TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides: the state of the art. Aboul-Fadl T Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780 [TBL] [Abstract][Full Text] [Related]
13. Antisense strategies for the treatment of hematological malignancies and solid tumors. Kronenwett R; Haas R Ann Hematol; 1998; 77(1-2):1-12. PubMed ID: 9760146 [TBL] [Abstract][Full Text] [Related]
14. Nucleic acid therapeutics: state of the art and future prospects. Gewirtz AM; Sokol DL; Ratajczak MZ Blood; 1998 Aug; 92(3):712-36. PubMed ID: 9680338 [No Abstract] [Full Text] [Related]
15. Applications of antisense oligonucleotides in oncology. Pierga JY; Magdelenat H Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172 [TBL] [Abstract][Full Text] [Related]
16. The potential application of ribozymes for the treatment of hematological disorders. James HA J Leukoc Biol; 1999 Sep; 66(3):361-8. PubMed ID: 10496304 [TBL] [Abstract][Full Text] [Related]